Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis
Version of Record online: 12 NOV 2012
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS
European Journal of Neurology
Volume 20, Issue 3, pages 527–533, March 2013
How to Cite
Stathis, P., Smpiliris, M., Konitsiotis, S. and Mitsikostas, D. D. (2013), Nocebo as a potential confounding factor in clinical trials for Parkinson's disease treatment: a meta-analysis. European Journal of Neurology, 20: 527–533. doi: 10.1111/ene.12014
- Issue online: 14 FEB 2013
- Version of Record online: 12 NOV 2012
- Manuscript Accepted: 17 SEP 2012
- Manuscript Received: 28 MAY 2012
Appendix S1. Studies included in the analysis for the estimation of the number of patients with at least one AE (21 studies).
Appendix S2. Studies included in the analysis for the estimation of the nocebo dropout rate (37 studies).
Appendix S3. Studies included in the analysis for the estimation of the AE incidence rate (32 studies).
|ene12014-sup-0002-TableS1.docx||Word document||24K||Table S1. The three most frequent adverse events (AEs) in placebo and active drug arms in all articles included in the analysis.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.